Study of Milnacipran for the Treatment of Fibromyalgia

This study has been completed.
Cypress Bioscience, Inc.
Information provided by:
Forest Laboratories Identifier:
First received: April 11, 2006
Last updated: January 14, 2010
Last verified: January 2010
The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia.

Condition Intervention Phase
Drug: Placebo
Drug: Milnacipran 100mg
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III Pivotal, Multicenter, Double-blind, Randomized, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia.

Resource links provided by NLM:

Further study details as provided by Forest Laboratories:

Primary Outcome Measures:
  • Composite Syndrome Responder Status [ Time Frame: At the end of the three-month stable dose treatment phase ] [ Designated as safety issue: No ]
  • Composite Pain Responder Status [ Time Frame: At the end of three-month stable dose treatment phase ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time-Weighted Average of Patient Experience Diary (PED) Reported Morning 24-Hour Recall Pain Scores for Weeks 1-12 of the Stable Dose Phase [ Time Frame: Weeks 1 through 12 of the stable dose treatment phase (Visit TX0-TX12) ] [ Designated as safety issue: No ]
  • Time-Weighted Average of Patient Global Impression of Change (PGIC) From Visit TX0-TX12. [ Time Frame: Weeks 1-12 (Visit TX0-TX12) of the stable dose treatment phase ] [ Designated as safety issue: No ]
  • Change From Baseline in the Multi-Dimensional Fatigue Inventory (MFI) Total Score at Visit TX12. [ Time Frame: Baseline through end of week 12 (Visit TX12) ] [ Designated as safety issue: No ]
  • Time-Weighted Average of the Short Form-36 Physical Component Summary (SF-36 PCS) Score From Visit TX0-TX12 [ Time Frame: Weeks 1-12 (Visit TX0-TX12) of the stable dose treatment phase ] [ Designated as safety issue: No ]

Enrollment: 1025
Study Start Date: April 2006
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo, oral administration, twice daily for 12 weeks
Drug: Placebo
Placebo, oral administration, twice daily for 12 weeks
Experimental: Milnacipran
Milnacipran 100mg/day (50mg BID [twice a day])
Drug: Milnacipran 100mg
Milnacipran 100mg per day (50mg BID [twice a day])


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) Criteria

Exclusion Criteria:

  • psychiatric illness,
  • depression,
  • suicidal risk,
  • substance abuse,
  • pulmonary dysfunction,
  • renal impairment,
  • active cardiac disease,
  • liver disease,
  • autoimmune disease,
  • cancer,
  • inflammatory bowel disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00314249

  Show 24 Study Locations
Sponsors and Collaborators
Forest Laboratories
Cypress Bioscience, Inc.
  More Information

No publications provided by Forest Laboratories

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Robert Palmer, MD, Forest Research Institute, a subsidiary of Forest Laboratories, Inc. Identifier: NCT00314249     History of Changes
Other Study ID Numbers: MLN-MD-03 
Study First Received: April 11, 2006
Results First Received: June 30, 2009
Last Updated: January 14, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Forest Laboratories:

Additional relevant MeSH terms:
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Nervous System Diseases
Neuromuscular Diseases
Rheumatic Diseases
Adrenergic Agents
Adrenergic Uptake Inhibitors
Antidepressive Agents
Central Nervous System Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses processed this record on February 08, 2016